Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

Inclusion Criteria: * Patients with hormone refractory prostate cancer * Patients must have metastatic disease with at least 1 measurable soft tissue lesion that can be assessed by CT or MRI and/or detectable lesion(s) on bone scintigraphy scan. Patients with only elevated PSA levels are not eligible for entry. * Patients must meet laboratory inclusion criteria defined in the protocol * Patients must be able to provide written informed consent Exclusion Criteria: * Patients with prior or concurrent brain metastases * Impaired cardiac, gastrointestinal, kidney or liver function * Use of therapeutic androgens Other protocol-defined inclusion/exclusion criteria may apply